

Prescient Therapeutics Announces Opening of 1st U.S. Site for PTX-100 Phase 2a Clinical Trial

Announcement Highlights:

- First US site initiation has been completed at one of the top cancer research centers in the US.
- This adds to 4 patients across 3 Australian sites and another significant step in the potential treatment for Cutaneous T-Cell Lymphoma (CTCL).
- Join CEO, James McDonnell, for an online investor briefing on Wednesday, 16th July at 2pm (AEST).

Register here: <https://prescienttherapeutics.investorportal.com.au/investor-briefing/>

MELBOURNE Australia, 16th July 2025: Prescient Therapeutics Limited (ASX: PTX), a clinical stage oncology company developing personalised therapies for cancer, is pleased to announce that the first U.S. Site Initiation Visit (SIV) has been completed. This marks another significant milestone in the progress of the Phase 2a trial for PTX-100 for patients suffering with refractory/relapsed Cutaneous T Cell Lymphoma (r/r CTCL).

Prescient Therapeutics CMO, Dr. Marissa Lim said “We are very pleased to have completed the first U.S. site initiation visit at the VCU Massey Comprehensive Cancer Center in Richmond, Virginia. This is part of the Virginia Commonwealth University (VCU) which is ranked as one of the top cancer research centers in the US. This site initiation marks the start of the U.S. recruitment into the Phase 2a trial, allowing U.S. patients to access PTX-100 through this trial.”

Professor Said Sebti, the Scientific Founder of Prescient Therapeutics said “As a cancer researcher, there is no greater fulfillment than seeing a drug you co-invented in the laboratory begin to touch patients’ lives; so the launch of this global Phase 2 clinical trial of PTX-100 in r/r CTCL, is one of the most exhilarating and humbling moments of my career, and a powerful reminder of what science can achieve when driven by purpose and passion. I’m profoundly proud that VCU Massey Comprehensive Cancer Center, my academic home, is the first U.S. site to open for patient accrual, bringing us one step closer to turning a long-held dream into meaningful impact for patients.”

Prescient Therapeutics CEO, James McDonnell offered, “The completion of the first SIV in the U.S. at VCU represents another step forward in the progress of our Phase 2a trial. The first U.S. site adds to the 3 Australian sites and 4 patients currently enrolled. We look forward to additional trial sites being initiated in the coming weeks, to add to the ongoing accrual of patients into the Phase 2a trial.”

Join a briefing

CEO James McDonnell will be holding a live and online investor briefing on Wednesday, 16th July at 2pm (AEST). Register here: <https://prescienttherapeutics.investorportal.com.au/investor-briefing/>

To stay updated with the latest company news and announcements, [please update your details](#) on our investor centre.

The Board of Prescient Therapeutics Limited has approved the release of this announcement.

For more information please contact:

Company enquiries

James McDonnell
CEO
Prescient Therapeutics
james.mcdonnell@ptxtherapeutics.com

Investor enquiries

Reach Markets
1300 805 795
ir@reachmarkets.com.au

About Prescient Therapeutics Limited (Prescient)

Prescient Therapeutics (ASX: PTX) is a clinical stage oncology company developing personalised medicine approaches to cancer, including targeted and cellular therapies.

Targeted Therapy

PTX-100: is a first in class compound with the ability to block an important cancer growth enzyme known as geranylgeranyl transferase-1 (GGT-1). It disrupts oncogenic Ras pathways by inhibiting the activation of Rho, Rac and Ral circuits in cancer cells, leading to apoptosis (death) of cancer cells. PTX- 100 is believed to be the only GGT-1 inhibitor in the world in clinical development. PTX-100 demonstrated safety and early clinical activity in a previous Phase 1 study and recent PK/PD basket study of hematological and solid malignancies. PTX-100 has recently completed a Phase 1b expansion cohort study in T cell lymphomas, where it showed encouraging efficacy and safety. The US FDA has granted PTX-100 Orphan Drug Designation for all T Cell Lymphomas and Fast Track Designation for the treatment of adults with relapsed or refractory (r/r) mycosis fungoides, the most common subtype of CTCL. A Phase 2 study in Cutaneous T cell lymphoma (CTCL) is recruiting globally and expects to enrol up to 40 patients in the phase 2a part of the trial.

Cell Therapy Platforms

CellPryme-M: Prescient's novel, ready-for-the-clinic, CellPryme-M technology enhances adoptive cell therapy performance by shifting T towards a central memory phenotype, improving persistence, and increasing the ability to find and penetrate tumours. CellPryme-M is a 24-hour, non-disruptive process during cell manufacturing. Cell therapies that could benefit from additional productivity in manufacturing or increased potency and durability in-vivo, would be good candidates for CellPryme-M.

CellPryme-A: CellPryme-A is an adjuvant therapy designed to be administered to patients alongside cellular immunotherapy to help them overcome a suppressive tumour microenvironment. CellPryme-A significantly decreases suppressive regulatory T cells; increases expansion of CAR-T cells in vivo; increases tumour

penetration of CAR-T cells. CellPryme-A improves tumour killing and host survival of CAR-T cell therapies, and these benefits are even greater when used in conjunction with CellPryme-M pre-treated CAR-T cells.

OmniCAR: is a universal immune receptor platform enabling controllable T-cell activity and multi- antigen targeting with a single cell product. OmniCAR's modular CAR system decouples antigen recognition from the T-cell signalling domain. It is the first universal immune receptor allowing post- translational covalent loading of binders to T-cells. OmniCAR is based on technology licensed from Penn; the SpyTag/SpyCatcher binding system licensed from Oxford University; and other assets. OmniCAR is in pre-clinical development.

The targeting ligand can be administered separately to CAR-T cells, creating on-demand T-cell activity post infusion and enables the CAR-T to be directed to an array of different tumour antigens. OmniCAR provides a method for single-vector, single cell product targeting of multiple antigens simultaneous or sequentially, whilst allowing continual re-arming to generate, regulate and diversify a sustained T-cell response over time.

Find out more at www.ptxtherapeutics.com or connect with us via [LinkedIn](#).

Disclaimer and Safe Harbor Statement

Certain statements made in this document are forward-looking statements within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. These forward-looking statements are not historical facts but rather are based on the current expectations of Prescient Therapeutics Limited ("Prescient" or the "Company"), their estimates, assumptions, and projections about the industry in which Prescient operates. Material referred to in this document that use the words 'estimate', 'project', 'intend', 'expect', 'plan', 'believe', 'guidance', and similar expressions are intended to identify forward-looking statements and should be considered an at-risk statement. These forward-looking statements are not a guarantee of future performance and involve known and unknown risks and uncertainties, some of which are beyond the control of Prescient or which are difficult to predict, which could cause the actual results, performance, or achievements of Prescient to be materially different from those which may be expressed or implied by these statements. These statements are based on current expectations and are subject to a number of uncertainties and risks that could change the results described in the forward-looking statements. Risks and uncertainties include, but are not limited to, general industry conditions and competition, general economic factors, global pandemics and related disruptions, the impact of pharmaceutical industry development and health care legislation in the United States and internationally, and challenges inherent in new product development. In particular, there are substantial risks in drug development including risks that studies fail to achieve an acceptable level of safety and/or efficacy. Investors should be aware that there are no assurances that results will not differ from those projected and Prescient cautions shareholders and prospective shareholders not to place undue reliance on these forward- looking statements, which reflect the view of Prescient only as of the date of this announcement. Prescient is not under a duty to update any forward-looking statement as a result of new information, future events or otherwise, except as required by law or by any appropriate regulatory authority.

Certain statements contained in this document, including, without limitation, statements containing the words "believes," "plans," "expects," "anticipates," and words of similar import, constitute "forward- looking statements." Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Prescient to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, among others, the following: the risk that our clinical trials will be delayed and not completed on a timely basis; the risk that the results from the clinical trials are not as favourable as we anticipate; the risk that our clinical trials will be more costly than anticipated; and the risk that applicable regulatory authorities may ask for additional data, information or studies to be completed or provided prior to their approval of our products. Given these uncertainties, undue reliance should not be placed on such forward-looking statements. The Company disclaims any obligation to update any such factors or to publicly announce the results of any revisions to any of the forward-looking statements contained herein to reflect future events or developments except as required by law.

This document may not contain all the details and information necessary for you to make a decision or evaluation. Neither this document nor any of its contents may be used for any other purpose without the prior written consent of the Company.